P D Good1, P J Ravenscroft, J Cavenagh. 1. Division of Palliative Care, Newcastle Mater Misericordiae Hospital, Waratah, New South Wales, Australia. Phillip.Good@mater.health.nsw.gov.au
Abstract
AIMS: To assess whether opioid and sedative medication use affects survival (from hospice admission to death) of patients in an Australian inpatient palliative care unit. BACKGROUND: Retrospective audit. Newcastle Mercy Hospice--a tertiary referral palliative care unit. All patients who died in the hospice between 1 February and 31 December 2000. METHODS: Length of survival from hospice admission to death, and the median and mean doses of opioids and sedatives used in the last 24 h of life. Comparison of these with published studies outside of Australia. RESULTS: In this study, the use of opioids, benzodiazepines and haloperidol did not have an association with shortened survival and the only statistical significant finding was an increased survival in patients who were on 300 mg/day or more of oral morphine equivalent (OME). The proportion of patients requiring greater than or equal to 300 mg OME/day (at 28%) was higher than published studies, but the mean dose of 371 mg OME/day was within the range of other studies. The proportion of patients receiving sedatives (94%) was higher than other studies, but the median dose of parenteral midazolam equivalent of 12.5 mg per 24 h was lower than other studies from outside Australia. CONCLUSIONS: There was no association between the doses of opioids and sedatives on the last day of life and survival (from hospice admission to death) in this population of palliative care patients.
AIMS: To assess whether opioid and sedative medication use affects survival (from hospice admission to death) of patients in an Australian inpatient palliative care unit. BACKGROUND: Retrospective audit. Newcastle Mercy Hospice--a tertiary referral palliative care unit. All patients who died in the hospice between 1 February and 31 December 2000. METHODS: Length of survival from hospice admission to death, and the median and mean doses of opioids and sedatives used in the last 24 h of life. Comparison of these with published studies outside of Australia. RESULTS: In this study, the use of opioids, benzodiazepines and haloperidol did not have an association with shortened survival and the only statistical significant finding was an increased survival in patients who were on 300 mg/day or more of oral morphine equivalent (OME). The proportion of patients requiring greater than or equal to 300 mg OME/day (at 28%) was higher than published studies, but the mean dose of 371 mg OME/day was within the range of other studies. The proportion of patients receiving sedatives (94%) was higher than other studies, but the median dose of parenteral midazolam equivalent of 12.5 mg per 24 h was lower than other studies from outside Australia. CONCLUSIONS: There was no association between the doses of opioids and sedatives on the last day of life and survival (from hospice admission to death) in this population of palliative care patients.
Authors: Veronica Dussel; Steven Joffe; Joanne M Hilden; Jan Watterson-Schaeffer; Jane C Weeks; Joanne Wolfe Journal: Arch Pediatr Adolesc Med Date: 2010-03
Authors: Tan Seng Beng; Carol Lai Cheng Kim; Chai Chee Shee; Diana Ng Leh Ching; Tan Jiunn Liang; Mehul Kumar Narendra Kumar; Ng Chong Guan; Lim Poh Khuen; Lam Chee Loong; Loh Ee Chin; Sheriza Izwa Zainuddin; David Paul Capelle; Ang Chui Munn; Lim Kah Yen; Nik Nathasha Hani Nik Isahak Journal: Am J Hosp Palliat Care Date: 2021-09-16 Impact factor: 2.090
Authors: Scott A Irwin; Rosene D Pirrello; Jeremy M Hirst; Gary T Buckholz; Frank D Ferris Journal: J Palliat Med Date: 2013-03-12 Impact factor: 2.947
Authors: Sander D Borgsteede; Christiaan A Rhodius; Peter A G M De Smet; H Roeline W Pasman; Bregje D Onwuteaka-Philipsen; Mette L Rurup Journal: Eur J Clin Pharmacol Date: 2010-09-19 Impact factor: 2.953
Authors: Mette L Rurup; Christiaan A Rhodius; Sander D Borgsteede; Manon Sa Boddaert; Astrid Gm Keijser; H Roeline W Pasman; Bregje D Onwuteaka-Philipsen Journal: BMC Palliat Care Date: 2010-11-12 Impact factor: 3.234